We are live on ! Find out more

Viatris

VTRS

Market cap $21.4B

18.67 USD

-0.37

1.94%

At close Updated Nov 2, 4:00 PM EST

Pre-market

After hours

18.62

-0.05

0.27%

1 day

-1.94%

5 days

2.64%

1 month

6.08%

3 months

5.9%

6 months

22.83%

Year to date

49.84%

1 year

77.3%

5 years

35%

10 years

-49.09%

About: Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.

Employees: 30,000

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 59.5%

Neutral 40.5%

Negative 0%

Zacks Investment Research

4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats

The third-quarter 2026 earnings season is revealing a familiar healthcare divide: demand is holding up, but not every business is turning that demand into stronger profits. Laboratories are ordering more equipment, cancer testing continues to expand, and animal health innovation is attracting customers.

4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats

Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.

PITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of Pacira BioSciences, Inc. ("Pacira") (Nasdaq: PCRX), for $36.50 per Share, in cash, net of applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated Oct. 30, 2026 (as it may be amended or supplemented from time to time, the "Offer to Purchase"), and the accompanying Letter of Transmittal (the "Letter of Transmittal" and, together with the Offer to Purchase and other related materials, as they may be amended or supplemented from time to time, the "Offer"). The Offer is being made pursuant to the Agreement and Plan of Merger, dated Oct. 8, 2026, by and among Viatris, Purchaser and Pacira (as it may be amended or supplemented from time to time, the "Merger Agreement").

Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.

Zacks Investment Research

Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?

Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research

Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?

Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?

Zacks Investment Research

Why Viatris (VTRS) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Viatris (VTRS) is a Top Momentum Stock for the Long-Term

Zacks Investment Research

Here's Why Viatris (VTRS) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Viatris (VTRS) is a Strong Value Stock

Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia

PITTSBURGH, Oct. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is currently approved in the United States for the treatment of pharmacologically-induced mydriasis and is the only commercially available FDA-approved product for that use.

Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira will receive $36.50 in cash for each share of Pacira that they own. KSF is seeking to determine whether this consideration and the process that led to it ar.

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

Zacks Investment Research

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

Buy Any Of 15 Ideal 'Safer' October Dogs Tenured Over 10 Years

I analyze 84 top Ten-Year tenured dividend dogs, focusing on yield-based selection and free cash flow safety for October 2026. Chimera Investment, Mach Natural Resources, and Matthews International lead projected net gains, with average estimated returns of 48.6% on $10k invested. Fifteen of thirty-six 'safer' dividend dogs meet the IDEAL standard, with annual dividends from $1k invested exceeding their share price.

Buy Any Of 15 Ideal 'Safer' October Dogs Tenured Over 10 Years

See News Rankings

Price charts implemented using Lightweight Charts™